New England Journal of Medicine· 2014Q1
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
- 3,219citations
- Q1SCImago
- 2014year
Short summary
First-line crizotinib significantly extended progression-free survival (PFS) by 3.9 months (median 10.9 vs. 7.0 months) and improved objective response rates (74% vs. 45%) compared to standard chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer (NSCLC).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine